Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) have been assigned an average recommendation of “Buy” from the twenty-six analysts that are currently covering the firm, MarketBeat.com reports. Eight research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $158.62.

A number of brokerages have recently issued reports on ALXN. Stifel Nicolaus reissued a “buy” rating and issued a $157.00 target price on shares of Alexion Pharmaceuticals in a report on Wednesday, May 24th. Jefferies Group LLC set a $120.00 target price on Alexion Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, June 8th. Royal Bank Of Canada restated an “outperform” rating and set a $177.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, March 27th. Barclays PLC restated an “overweight” rating and set a $155.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 9th. Finally, Morgan Stanley restated an “overweight” rating and set a $138.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, June 14th.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 0.13% on Friday, reaching $126.07. The company had a trading volume of 4,530,700 shares. The company has a 50-day moving average of $112.77 and a 200 day moving average of $122.35. The stock has a market cap of $28.31 billion, a price-to-earnings ratio of 60.06 and a beta of 1.45. Alexion Pharmaceuticals has a one year low of $96.18 and a one year high of $145.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.38 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.33. Alexion Pharmaceuticals had a return on equity of 11.72% and a net margin of 14.52%. The business had revenue of $870 million during the quarter, compared to analysts’ expectations of $826.63 million. During the same period in the prior year, the firm posted $1.11 EPS. Alexion Pharmaceuticals’s quarterly revenue was up 24.3% compared to the same quarter last year. On average, equities research analysts predict that Alexion Pharmaceuticals will post $5.31 EPS for the current year.

In related news, Director Bros. Advisors Lp Baker purchased 660,779 shares of Alexion Pharmaceuticals stock in a transaction dated Thursday, June 15th. The shares were acquired at an average cost of $117.33 per share, for a total transaction of $77,529,200.07. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Ludwig Hantson purchased 10,000 shares of Alexion Pharmaceuticals stock in a transaction dated Wednesday, June 14th. The stock was bought at an average price of $116.72 per share, for a total transaction of $1,167,200.00. Following the completion of the transaction, the chief executive officer now directly owns 38,725 shares in the company, valued at $4,519,982. The disclosure for this purchase can be found here. Insiders bought a total of 2,019,734 shares of company stock worth $235,606,846 over the last 90 days. 4.35% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of ALXN. BlackRock Inc. raised its position in Alexion Pharmaceuticals by 2,689.8% in the first quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock valued at $2,258,467,000 after buying an additional 17,960,356 shares in the last quarter. Vanguard Group Inc. raised its position in Alexion Pharmaceuticals by 3.1% in the first quarter. Vanguard Group Inc. now owns 14,467,456 shares of the biopharmaceutical company’s stock valued at $1,754,034,000 after buying an additional 433,293 shares in the last quarter. State Street Corp raised its position in Alexion Pharmaceuticals by 6.8% in the first quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock valued at $1,369,846,000 after buying an additional 718,756 shares in the last quarter. Jennison Associates LLC raised its position in Alexion Pharmaceuticals by 15.8% in the first quarter. Jennison Associates LLC now owns 9,622,914 shares of the biopharmaceutical company’s stock valued at $1,166,682,000 after buying an additional 1,309,529 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its position in Alexion Pharmaceuticals by 8.0% in the first quarter. Ameriprise Financial Inc. now owns 6,149,572 shares of the biopharmaceutical company’s stock valued at $745,579,000 after buying an additional 454,069 shares in the last quarter. Institutional investors and hedge funds own 94.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was originally published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/06/23/alexion-pharmaceuticals-inc-alxn-receives-average-recommendation-of-buy-from-brokerages.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.